Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrexafungerp (Primary) ; Anidulafungin; Caspofungin; Fluconazole; Micafungin; Voriconazole
  • Indications Candidaemia; Invasive candidiasis
  • Focus Registrational; Therapeutic Use
  • Acronyms MARIO
  • Sponsors SCYNEXIS

    • Most Recent Events

    • 23 Jul 2024 According to a Scynexis media release, company is looking forward to reestablish the supply chain of ibrexafungerp and restarting the Phase 3 MARIO study in invasive candidiasis.
    • 08 May 2024 According to a Scynexis media release , company has entered into certain new manufacturing agreements with third-party contract manufacturers to begin producing new batches of ibrexafungerp which will allow to lift the clinical hold and restart the Phase 3 MARIO study
    • 16 Nov 2023 According to a Scynexis media release ,status changed from recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top